Is there a role for PDE5 inhibitors in the management of male infertility due to defects in testicular or epididymal function?

Current Pharmaceutical Design

Volumn 15, Issue 30, 2009, Pages 3506-3520

  Dimitriadis, F ^a,b   Tsounapi, P ^b   Saito, M ^b   Watanabe, T ^b   Sylakos, A ^a   Tsabalas, S ^a   Miyagawa, I ^b   Sofikitis, N ^a,b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b TOTTORI UNIVERSITY   (Japan)

Author keywords

Epididymis; Phosphodiesterase; Spermatozoa; Testis

Indexed keywords

CYCLIC GMP; PENTOXIFYLLINE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; TADALAFIL; THEOPHYLLINE; VARDENAFIL;

CLINICAL TRIAL; DRUG EFFICACY; ERECTILE DYSFUNCTION; GENE EXPRESSION; GENE FUNCTION; HUMAN; HYDROLYSIS; INFERTILITY THERAPY; LEYDIG CELL; MALE INFERTILITY; NONHUMAN; OLIGOSPERMIA; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROSTATITIS; REVIEW; SEMEN ANALYSIS; SERTOLI CELL; SEXUAL SATISFACTION; SINGLE DRUG DOSE; SPERMATOZOON COUNT; SPERMATOZOON MOTILITY; TREATMENT DURATION; TREATMENT RESPONSE;

ACROSOME REACTION; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; EPIDIDYMIS; GENITAL DISEASES, MALE; GENITALIA, MALE; HUMANS; INFERTILITY, MALE; LEYDIG CELLS; MALE; PHOSPHODIESTERASE INHIBITORS; SEMEN; SEMINIFEROUS TUBULES; SERTOLI CELLS; SPERM CAPACITATION; SPERMATOZOA; TESTICULAR DISEASES;

EID: 70449434697     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209789207015     Document Type: Review

References (153)

1. Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 2006; 58: 488-520.
2. Zaccolo M, Pozzan T. Discrete microdomains with high concentration of cAMP in stimulated rat neonatal cardiac myocytes. Science 2002; 295: 1711-1715 (Pubitemid 34202906)
3. Lue TF. Erectile dysfunction. N Engl J Med 2000; 342: 1802-1813
4. Ghofrani HA, Wiedemann R, Rose F, Olschewski H, Schermuly RT, Weissmann N, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002; 136: 515-522 (Pubitemid 34252285)
5. Ghofrani HA, Olschewski H, Seeger W, Grimminger F. Sildenafil for treatment of severe pulmonary hypertension and commencing right-heart failure. Pneumologie 2002; 56: 665-672 (Pubitemid 35434189)
6. Ghofrani HA, Schermuly RT, Rose F, Wiedemann R, Kohstall MG, Kreckel A, et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2003; 167: 1139-1141 (Pubitemid 36459662)
7. Schermuly RT, Kreisselmeier KP, Ghofrani HA, Yilmaz H, Butrous G, Ermert L, et al. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med 2004; 169: 39-45. (Pubitemid 38233887)
8. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-2157 (Pubitemid 41653106)
9. Fujishige K, Kotera J, Michibata H, Yuasa K, Takebayashi S, Okumura K, et al. Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J Biol Chem 1999; 274: 18438-18445 (Pubitemid 129519246)
10. Scipioni A, Stefanini S, Santone R, Giorgi M. Immunohistochemical localisation of PDE5 in Leydig and myoid cells of prepuberal and adult rat testis. Histochem Cell Biol 2005; 124: 401-407 (Pubitemid 41547557)
11. Setchell BP, Maddocks S, Brooks DE. Knobil E, Neill JD, Eds. In: The Physiology of Reproduction. New York: Raven Press 1994; pp. 1063-1175
12. Davidoff MS, Breucker H, Holstein AF, Seidl K. Cellular architecture of the lamina propria of human seminiferous tubules. Cell Tissue Res 1990; 262: 253-261 (Pubitemid 20344865)
13. Zhang C, Yeh S, Chen YT, Wu CC, Chuang KH, Lin HY, et al. Oligozoospermia with normal fertility in male mice lacking the androgen receptor in testis peritubular myoid cells. Proc Natl Acad Sci USA 2006; 103: 17718-17723 (Pubitemid 44852226)
14. Mewe M, Bauer CK, Muller D, Middendorff R. Regulation of spontaneous contractile activity in the bovine epididymal duct by cyclic guanosine 5'-monophosphate-dependent pathways. Endocrinology 2006; 147: 2051-2062
15. Swinnen JV, Joseph DR, Conti M. Molecular cloning of rat homologues of the Drosophila melanogaster dunce cAMP phosphodiesterase: evidence for a family of genes. Proc Natl Acad Sci USA 1989; 86: 5325-5329 (Pubitemid 19185546)
16. Geremia R, Rossi P, Pezzotti R, Conti M. Cyclic nucleotide phosphodiesterase in developing rat testis. Identification of somatic and germ-cell forms. Mol Cell Endocrinol 1982; 28: 37-53.
17. Morena AR, Boitani C, de Grossi S, Stefanini M, Conti M. Stage and cell-specific expression of the adenosine 3′,5′ monophosphatephosphodiesterase genes in the rat seminiferous epithelium. Endocrinology 1995; 136: 687-695
18. Sette C, Iona S, Conti M. The short-term activation of a rolipramsensitive, cAMP-specific phosphodiesterase by thyroid-stimulating hormone in thyroid FRTL-5 cells is mediated by a cAMP-dependent phosphorylation. J Biol Chem 1994; 269: 9245-9252 (Pubitemid 24209251)
19. Coskran TM, Morton D, Menniti FS, Adamowicz WO, Kleiman RJ, Ryan AM, et al. Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species. J Histochem Cytochem 2006; 54: 1205-1213 (Pubitemid 44623341)
20. Fujishige K, Kotera J, Omori K. Striatum- and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10A. Eur J Biochem 1999; 266: 1118-1127 (Pubitemid 30010131)
21. Soderling SH, Bayuga SJ, Beavo JA. Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase. Proc Natl Acad Sci USA 1998; 95: 8991-8996 (Pubitemid 28350602)
22. Baxendale RW, Fraser LR. Mammalian sperm phosphodiesterases and their involvement in receptor-mediated cell signaling important for capacitation. Mol Reprod Dev 2005; 71: 495-508.
23. Siuciak JA, McCarthy SA, Chapin DS, Fujiwara RA, James LC, Williams RD, et al. Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function. Neuropharmacology 2006; 51: 374-385
24. Francis SH. Phosphodiesterase 11 (PDE11): is it a player in human testicular function? Int J Impot Res 2005; 17: 467-8.
25. Wayman C, Phillips S, Lunny C, Webb T, Fawcett L, Baxendale R, et al. Phosphodiesterase 11 (PDE11) regulation of spermatozoa physiology. Int J Impot Res 2005; 17: 216-223
26. Middendorff R, Muller D, Mewe M, Mukhopadhyay AK, Holstein AF, Davidoff MS. The tunica albuginea of the human testis is characterized by complex contraction and relaxation activities regulated by cyclic GMP. J Clin Endocrinol Metab 2002; 87: 3486-3499 (Pubitemid 34816407)
27. Muller D, Mukhopadhyay AK, Speth RC, Guidone G, Potthast R, Potter LR, et al. Spatiotemporal regulation of the two atrial natriuretic peptide receptors in testis. Endocrinology 2004; 145: 1392-1401 (Pubitemid 38281024)
28. Yuasa K, Omori K, Yanaka N. Binding and phosphorylation of a novel male germ cell-specific cGMP-dependent protein kinase-anchoring protein by cGMP-dependent protein kinase Ialpha. J Biol Chem 2000; 275: 4897-4905 (Pubitemid 30108883)
29. Kishimoto I, Rossi K, Garbers DL. A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy. Proc Natl Acad Sci USA 2001; 98: 2703-2706 (Pubitemid 32209546)
30. Lelievre V, Pineau N, Hu Z, Ioffe Y, Byun JY, Muller JM, et al. Proliferative actions of natriuretic peptides on neuroblastoma cells. Involvement of guanylyl cyclase and non-guanylyl cyclase pathways. J Biol Chem 2001; 276: 43668-43676 (Pubitemid 37383928)
31. Silberbach M, Roberts CT, Jr. Natriuretic peptide signalling: molecular and cellular pathways to growth regulation. Cell Signal 2001; 13: 221-231
32. Cameron VA, Ellmers LJ. Minireview: natriuretic peptides during development of the fetal heart and circulation. Endocrinology 2003; 144: 2191-4.
33. Anderson RA, Jr., Feathergill KA, Rawlins RG, Mack SR, Zaneveld LJ. Atrial natriuretic peptide: a chemoattractant of human spermatozoa by a guanylate cyclase-dependent pathway. Mol Reprod Dev 1995; 40: 371-378
34. Rotem R, Zamir N, Keynan N, Barkan D, Breitbart H, Naor Z. Atrial natriuretic peptide induces acrosomal exocytosis of human spermatozoa. Am J Physiol 1998; 274: E218-23. (Pubitemid 128731708)
35. Middendorff R, Davidoff MS, Behrends S, Mewe M, Miethens A, Muller D. Multiple roles of the messenger molecule cGMP in testicular function. Andrologia 2000; 32: 55-59 (Pubitemid 30090287)
36. Middendorff R, Muller D, Paust HJ, Davidoff MS, Mukhopadhyay AK. Natriuretic peptides in the human testis: evidence for a potential role of C-type natriuretic peptide in Leydig cells. J Clin Endocrinol Metab 1996; 81: 4324-4328 (Pubitemid 26412037)
37. Middendorff R, Kumm M, Davidoff MS, Holstein AF, Muller D. Generation of cyclic guanosine monophosphate by heme oxygenases in the human testis - a regulatory role for carbon monoxide in Sertoli cells? Biol Reprod 2000; 63: 651-657
38. Middendorff R, Muller D, Wichers S, Holstein AF, Davidoff MS. Evidence for production and functional activity of nitric oxide in seminiferous tubules and blood vessels of the human testis. J Clin Endocrinol Metab 1997; 82: 4154-4161 (Pubitemid 27525531)
39. Maekawa M, Kamimura K, Nagano T. Peritubular myoid cells in the testis: their structure and function. Arch Histol Cytol 1996; 59: 1-13. (Pubitemid 26117360)
40. Eskild W, Hansson V. In: Blomhoff R, Ed. Vitamin A in Health and Disease. New York: Marcel Dekker, Inc. 1994; pp. 531-559
41. Dimitriadis F, Giannakis D, Pardalidis N, Zikopoulos K, Paraskevaidis E, Giotitsas N, et al. Effects of phosphodiesterase-5 inhibitors on sperm parameters and fertilizing capacity. Asian J Androl 2008; 10: 115-133
42. Dimitriadis F, Tsiriopoulos I, Baltogiannis D, Tsounapi P, Gratsias S, Vlachopoulou E, et al. Effects of phosphodiesterase-5 inhibitors on Leydig cell secretory function. 24th annual EUA Congress. March 17th-21st 2009, Stockholm. Eur Urol Suppl 2009; 8: 215.
43. Saez JM. Leydig cells: endocrine, paracrine, and autocrine regulation. Endocr Rev 1994; 15: 574-626.
44. Stocco DM, Wang X, Jo Y, Manna PR. Multiple signaling pathways regulating steroidogenesis and steroidogenic acute regulatory protein expression: more complicated than we thought. Mol Endocrinol 2005; 19: 2647-2659 (Pubitemid 41577240)
45. Catt KJ, Dufau ML. Spare gonadotrophin receptors in rat testis. Nat New Biol 1973; 244: 219-221
46. Mendelson C, Dufau M, Catt K. Gonadotropin binding and stimulation of cyclic adenosine 3':5'-monophosphate and testosterone production in isolated Leydig cells. J Biol Chem 1975; 250: 8818-8823
47. Vasta V, Shimizu-Albergine M, Beavo JA. Modulation of Leydig cell function by cyclic nucleotide phosphodiesterase 8A. Proc Natl Acad Sci USA 2006; 103: 19925-19930 (Pubitemid 46037532)
48. Fisher DA, Smith JF, Pillar JS, St Denis SH, Cheng JB. Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase. Biochem Biophys Res Commun 1998; 246: 570-577 (Pubitemid 28420898)
49. Glavas NA, Ostenson C, Schaefer JB, Vasta V, Beavo JA. T cell activation up-regulates cyclic nucleotide phosphodiesterases 8A1 and 7A3. Proc Natl Acad Sci USA 2001; 98: 6319-6324 (Pubitemid 32488237)
50. Vlachopoulou E, Tsiriopoulos I, Dimitriadis F, Baltogiannis D, Miyagawa I, Sofikitis N. Effects of vardenafil on Sertoli cell secretory function. 24th annual EUA Congress. March 17th-21st 2009, Stockholm. Eur Urol Suppl 2009; 8: 148.
51. Conti M, Toscano MV, Petrelli L, Geremia R, Stefanini M. Regulation of follicle-stimulating hormone and dibutyryl adenosine 3′,5′- monophosphate of a phosphodiesterase isoenzyme of the Sertoli cell. Endocrinology 1982; 110: 1189-96.
52. Rossi P, Pezzotti R, Conti M, Geremia R. Cyclic nucleotide phosphodiesterases in somatic and germ cells of mouse seminiferous tubules. J Reprod Fertil 1985; 74: 317-27.
53. Conti M, Iona S, Cuomo M, Swinnen JV, Odeh J, Svoboda ME. Characterization of a hormone-inducible, high affinity adenosine 3′-5′-cyclic monophosphate phosphodiesterase from the rat Sertoli cell. Biochemistry 1995; 34: 7979-87.
54. Zhao AZ, Yan C, Sonnenburg WK, Beavo JA. Recent advances in the study of Ca2+/CaM-activated phosphodiesterases: expression and physiological functions. Adv Second Messenger Phosphoprotein Res 1997; 31: 237-51.
55. Ricker DD. The autonomic innervation of the epididymis: its effects on epididymal function and fertility. J Androl 1998; 19: 1-4.
56. Mewe M, Bauer CK, Schwarz JR, Middendorff R. Mechanisms regulating spontaneous contractions in the bovine epididymal duct. Biol Reprod 2006; 75: 651-9.
57. Mulryan K, Gitterman DP, Lewis CJ, Vial C, Leckie BJ, Cobb AL, et al. Reduced vas deferens contraction and male infertility in mice lacking P2X1 receptors. Nature 2000; 403: 86-9.
58. Tamura N, Doolittle LK, Hammer RE, Shelton JM, Richardson JA, Garbers DL. Critical roles of the guanylyl cyclase B receptor in endochondral ossification and development of female reproductive organs. Proc Natl Acad Sci USA 2004; 101: 17300-5.
59. Lucas KA, Pitari GM, Kazerounian S, Ruiz-Stewart I, Park J, Schulz S, et al. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 2000; 52: 375-414.
60. Glover TD, Nicander L. Some aspects of structure and function in the mammalian epididymis. J Reprod Fertil Suppl 1971; 13: (Suppl 13): 39-50.
61. Abdel-Hamid IA. Phosphodiesterase 5 inhibitors in rapid ejaculation: potential use and possible mechanisms of action. Drugs 2004; 64: 13-26.
62. Chen J, Mabjeesh NJ, Matzkin H, Greenstein A. Efficacy of sildenafil as adjuvant therapy to selective serotonin reuptake inhibitor in alleviating premature ejaculation. Urology 2003; 61: 197-200.
63. Sundkvist E, Jaeger R, Sager G. Pharmacological characterization of the ATP-dependent low K(m) guanosine 3′,5′-cyclic monophosphate (cGMP) transporter in human erythrocytes. Biochem Pharmacol 2002; 63: 945-9.
64. Medina P, Segarra G, Torondel B, Chuan P, Domenech C, Vila JM, et al. Inhibition of neuroeffector transmission in human vas deferens by sildenafil. Br J Pharmacol 2000; 131: 871-4.
65. Bilge SS, Kesim Y, Kurt M, Aksoz E, Celik S. Possible role of sildenafil in inhibiting rat vas deferens contractions by influencing the purinergic system. Int J Urol 2005; 12: 829-34.
66. Ponchietti R, Raugei A, Lanciotti E, Ademollo B, Galvan P, Poggini G. Calcium, zinc, magnesium, concentration in seminal plasma of infertile men with prostatitis. Acta Eur Fertil 1984; 15: 283-5.
67. Fair WR, Couch J, Wehner N. The purification and assay of the prostatic antibacterial factor (PAF). Biochem Med 1973; 8: 329-39.
68. Meares EM, Jr. Prostatitis. Med Clin North Am 1991; 75: 405-24.
69. Burnett AL, Maguire MP, Chamness SL, Ricker DD, Takeda M, Lepor H, et al. Characterization and localization of nitric oxide synthase in the human prostate. Urology 1995; 45: 435-9.
70. Takeda M, Tang R, Shapiro E, Burnett AL, Lepor H. Effects of nitric oxide on human and canine prostates. Urology 1995; 45: 440-6.
71. Uckert S, Kuthe A, Jonas U, Stief CG. Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 2001; 166: 2484-90.
72. Grimsley SJ, Khan MH, Jones GE. Mechanism of Phosphodiesterase 5 inhibitor relief of prostatitis symptoms. Med Hypotheses 2007; 69: 25-6.
73. Yuasa K, Kanoh Y, Okumura K, Omori K. Genomic organization of the human phosphodiesterase PDE11A gene. Evolutionary relatedness with other PDEs containing GAF domains. Eur J Biochem 2001; 268: 168-78.
74. Loughney K, Taylor J, Florio VA. 3′,5′-cyclic nucleotide phosphodiesterase 11A: localization in human tissues. Int J Impot Res 2005; 17: 320-5.
75. Fisch JD, Behr B, Conti M. Enhancement of motility and acrosome reaction in human spermatozoa: differential activation by type-specific phosphodiesterase inhibitors. Hum Reprod 1998; 13: 1248-54.
76. Sikka SC, Hellstrom WJ. The application of pentoxifylline in the stimulation of sperm motion in men undergoing electroejaculation. J Androl 1991; 12: 165-70.
77. Tesarik J, Thebault A, Testart J. Effect of pentoxifylline on sperm movement characteristics in normozoospermic and asthenozoospermic specimens. Hum Reprod 1992; 7: 1257-63.
78. Tournaye H, Devroey P, Camus M, Van der Linden M, Janssens R, Van Steirteghem A. Use of pentoxifylline in assisted reproductive technology. Hum Reprod 1995; 10 (Suppl 1): 72-9.
79. Schill WB, Pritsch W, Preissler G. Effect of caffeine and kallikrein on cryo-preserved human spermatozoa. Int J Fertil 1979; 24: 27-32.
80. Schill WB. Caffeine- and kallikrein-induced stimulation of human sperm motility: a comparative study. Andrologia 1975; 7: 229-36.
81. De Turner E, Aparicio NJ, Turner D, Schwarzstein L. Effect of two phosphodiesterase inhibitors, cyclic adenosine 3′:5′-monophosphate, and a beta-blocking agent on human sperm motility. Fertil Steril 1978; 29: 328-31.
82. Haesungcharern A, Chulavatnatol M. Stimulation of human spermatozoal motility by caffeine. Fertil Steril 1973; 24: 662-5.
83. Jaiswal BS, Majumder GC. Cyclic AMP phosphodiesterase: a regulator of forward motility initiation during epididymal sperm maturation. Biochem Cell Biol 1996; 74: 669-74.
84. Rees JM, Ford WC, Hull MG. Effect of caffeine and of pentoxifylline on the motility and metabolism of human spermatozoa. J Reprod Fertil 1990; 90: 147-56.
85. Levin RM, Greenberg SH, Wein AJ. Quantitative analysis of the effects of caffeine on sperm motility and cyclic adenosine 3′,5′-monophosphate (AMP) phosphodiesterase. Fertil Steril 1981; 36: 798-802.
86. Tesarik J, Mendoza C, Carreras A. Effect of phosphodiesterase inhibitors, caffeine and pentoxifylline, on spontaneous and stimulus-induced acrosome reactions in human sperm. Fertil Steril 1992; 58: 1185-90.
87. Wang C, Chan CW, Wong KK, Yeung KK. Comparison of the effectiveness of placebo, clomiphene citrate, mesterolone, pentoxifylline, and testosterone rebound therapy for the treatment of idiopathic oligospermia. Fertil Steril 1983; 40: 358-65.
88. Marrama P, Baraghini GF, Carani C, Celani MF, Giovenco P, Grandi F, et al. Further studies on the effects of pentoxifylline on sperm count and sperm motility in patients with idiopathic oligoasthenozoospermia. Andrologia 1985; 17: 612-6.
89. Shen MR, Chiang PH, Yang RC, Hong CY, Chen SS. Pentoxifylline stimulates human sperm motility both in vitro and after oral therapy. Br J Clin Pharmacol 1991; 31: 711-4.
90. Pang SC, Chan PJ, Lu A. Effects of pentoxifylline on sperm motility and hyperactivation in normozoospermic and normokinetic semen. Fertil Steril 1993; 60: 336-43.
91. Fuse H, Sakamoto M, Ohta S, Katayama T. Effect of pentoxifylline on sperm motion. Arch Androl 1993; 31: 9-15.
92. Tournaye H, Van Steirteghem AC, Devroey P. Pentoxifylline in idiopathic male-factor infertility: a review of its therapeutic efficacy after oral administration. Hum Reprod 1994; 9: 996-1000.
93. Yovich JM, Edirisinghe WR, Cummins JM, Yovich JL. Preliminary results using pentoxifylline in a pronuclear stage tubal transfer (PROST) program for severe male factor infertility. Fertil Steril 1988; 50: 179-81.
94. Yovich JM, Edirisinghe WR, Cummins JM, Yovich JL. Influence of pentoxifylline in severe male factor infertility. Fertil Steril 1990; 53: 715-22.
95. Tasdemir M, Tasdemir I, Kodama H, Tanaka T. Pentoxifylline-enhanced acrosome reaction correlates with fertilization in vitro. Hum Reprod 1993; 8: 2102-7.
96. Yunes R, Fernandez P, Doncel GF, Acosta AA. Cyclic nucleotide phosphodiesterase inhibition increases tyrosine phosphorylation and hyper motility in normal and pathological human spermatozoa. Biocell 2005; 29: 287-93.
97. Stefanovich V. Effect of 3,7-dimethyl-1-(5-oxo-hexyl)xanthine and 1-hexyl-3,7-dimethyl xanthine on cyclic AMP phosphodiesterase of the human umbilical cord vessels. Res Commun Chem Pathol Pharmacol 1973; 5: 655-62.
98. Garbers DL, Kopf GS. The regulation of spermatozoa by calcium cyclic nucleotides. Adv Cyclic Nucleotide Res 1980; 13: 251-306.
99. Tash JS, Means AR. Cyclic adenosine 3′,5′ monophosphate, calcium and protein phosphorylation in flagellar motility. Biol Reprod 1983; 28: 75-104.
100. Ward A, Clissold SP. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 1987; 34: 50-97.
101. Twigg J, Fulton N, Gomez E, Irvine DS, Aitken RJ. Analysis of the impact of intracellular reactive oxygen species generation on the structural and functional integrity of human spermatozoa: lipid peroxidation, DNA fragmentation and effectiveness of antioxidants. Hum Reprod 1998; 13: 1429-36.
102. Lopes S, Jurisicova A, Sun JG, Casper RF. Reactive oxygen species: potential cause for DNA fragmentation in human spermatozoa. Hum Reprod 1998; 13: 896-900.
103. Lewis SE, Moohan JM, Thompson W. Effects of pentoxifylline on human sperm motility in normospermic individuals using computer-assisted analysis. Fertil Steril 1993; 59: 418-23.
104. Moohan JM, Winston RM, Lindsay KS. Variability of human sperm response to immediate and prolonged exposure to pentoxifylline. Hum Reprod 1993; 8: 1696-700.
105. Centola GM, Cartie RJ, Cox C. Differential responses of human sperm to varying concentrations of pentoxifylline with demonstration of toxicity. J Androl 1995; 16: 136-42.
106. Paul M, Sumpter JP, Lindsay KS. Factors affecting pentoxifylline stimulation of sperm kinematics in suspensions. Hum Reprod 1996; 11: 1929-35.
107. Nassar A, Mahony M, Morshedi M, Lin MH, Srisombut C, Oehninger S. Modulation of sperm tail protein tyrosine phosphorylation by pentoxifylline and its correlation with hyperactivated motility. Fertil Steril 1999; 71: 919-23.
108. Purvis K, Muirhead GJ, Harness JA. The effects of sildenafil on human sperm function in healthy volunteers. Br J Clin Pharmacol 2002; 53 (Suppl 1): 53S-60S.
109. Aversa A, Mazzilli F, Rossi T, Delfino M, Isidori AM, Fabbri A. Effects of sildenafil (Viagra) administration on seminal parameters and post-ejaculatory refractory time in normal males. Hum Reprod 2000; 15: 131-4.
110. Tur-Kaspa I, Segal S, Moffa F, Massobrio M, Meltzer S. Viagra for temporary erectile dysfunction during treatments with assisted reproductive technologies. Hum Reprod 1999; 14: 1783-4.
111. du Plessis SS, de Jongh PS, Franken DR. Effect of acute in vivo sildenafil citrate and in vitro 8-bromo-cGMP treatments on semen parameters and sperm function. Fertil Steril 2004; 81: 1026-33.
112. Jannini EA, Lombardo F, Salacone P, Gandini L, Lenzi A. Treatment of sexual dysfunctions secondary to male infertility with sildenafil citrate. Fertil Steril 2004; 81: 705-7.
113. Lenzi A, Lombardo F, Salacone P, Gandini L, Jannini EA. Stress, sexual dysfunctions, and male infertility. J Endocrinol Invest 2003; 26: 72-6.
114. Sofikitis N, Miyagawa I. Secretory dysfunction of the male accessory genital glands due to prostatic infections and fertility; a selected review of the literature. Jpn J Fertil Steril 1991; 36: 690-9.
115. Portnoy L. The diagnosis and prognosis of male infertility: a study of 44 cases with special reference to sperm morphology. J Urol 1946; 48: 735.
116. Sofikitis NV, Miyagawa I. Endocrinological, biophysical, and biochemical parameters of semen collected via masturbation versus sexual intercourse. J Androl 1993; 14: 366-73.
117. Yamamoto Y, Sofikitis N, Mio Y, Miyagawa I. Influence of sexual stimulation on sperm parameters in semen samples collected via masturbation from normozoospermic men or cryptozoospermic men participating in an assisted reproduction programme. Andrologia 2000; 32: 131-8.
118. Salisbury GW, Vandermark NL. In: No Editors. A Series of books in animal science. San Francisco and London, Freeman. 1961; 395-6.
119. Sharma OP, Hays RL. Release of an oxytocic substance following genital stimulation in bulls. J Reprod Fertil 1973; 35: 359-62.
120. Hafs HD, Knisely RC, Desjardens C. Sperm output of dairy bulls with varying degrees of sexual preparation. J Dairy Sci 1962; 35: 359-62.
121. Ali ST, Rakkah NI. Neurophysiological role of sildenafil citrate (Viagra) on seminal parameters in diabetic males with and without neuropathy. Pak J Pharm Sci 2007; 20: 36-42.
122. Pomara G, Morelli G, Canale D, Turchi P, Caglieresi C, Moschini C, et al. Alterations in sperm motility after acute oral administration of sildenafil or tadalafil in young, infertile men. Fertil Steril 2007; 88: 860-5.
123. Nomura M, Vacquier VD. Proteins associated with soluble adenylyl cyclase in sea urchin sperm flagella. Cell Motil Cytoskeleton 2006; 63: 582-90.
124. Hellstrom WJ, Overstreet JW, Yu A, Saikali K, Shen W, Beasley CM, Jr., et al. Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones. J Urol 2003; 170: 887-91.
125. Hellstrom WJ, Gittelman M, Jarow J, Steidle C, McMurray J, Talley D, et al. An evaluation of semen characteristics in men 45 years of age or older after daily dosing with tadalafil 20mg: results of a multicenter, randomized, double-blind, placebo-controlled, 9-month study. Eur Urol 2008; 53: 1058-65.
126. Bauer RJ, Rohde G. A single oral dose of vardenafil had no acute effect on sperm motility in healthy males. 27th Annual Meeting of the American Society of Andrology. April 24-27, 2002. Seattle, Washington, USA. J Androl 2002; (Suppl): 26.
127. Jarvi K, Dula E, Drehobl M, Pryor J, Shapiro J, Seger M. Daily vardenafil for 6 months has no detrimental effects on semen characteristics or reproductive hormones in men with normal baseline levels. J Urol 2008; 179: 1060-5.
128. Burger M, Sikka SC, Bivalacqua TJ, Lamb DJ, Hellstrom WJ. The effect of sildenafil on human sperm motion and function from normal and infertile men. Int J Impot Res 2000; 12: 229-34.
129. Andrade JR, Traboulsi A, Hussain A, Dubin NH. In vitro effects of sildenafil and phentolamine, drugs used for erectile dysfunction, on human sperm motility. Am J Obstet Gynecol 2000; 182: 1093-5.
130. Su YH, Vacquier VD. Cyclic GMP-specific phosphodiesterase-5 regulates motility of sea urchin spermatozoa. Mol Biol Cell 2006; 17: 114-21.
131. Mostafa T. In vitro sildenafil citrate use as a sperm motility stimulant. Fertil Steril 2007; 88: 994-6.
132. Lefievre L, De Lamirande E, Gagnon C. The cyclic GMP-specific phosphodiesterase inhibitor, sildenafil, stimulates human sperm motility and capacitation but not acrosome reaction. J Androl 2000; 21: 929-37.
133. Cuadra DL, Chan PJ, Patton WC, Stewart SC, King A. Type 5 phosphodiesterase regulation of human sperm motility. Am J Obstet Gynecol 2000; 182: 1013-5.
134. Glenn DR, McVicar CM, McClure N, Lewis SE. Sildenafil citrate improves sperm motility but causes a premature acrosome reaction in vitro. Fertil Steril 2007; 87: 1064-70.
135. Mostafa T. Tadalafil as an in vitro sperm motility stimulant. Andrologia 2007; 39: 12-5.
136. Biel M, Sautter A, Ludwig A, Hofmann F, Zong X. Cyclic nucleotide-gated channels--mediators of NO: cGMP-regulated processes. Naunyn Schmiedebergs Arch Pharmacol 1998; 358: 140-4.
137. Dousa TP. Cyclic-3′,5′-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney. Kidney Int 1999; 55: 29-62.
138. Kotera J, Fujishige K, Imai Y, Kawai E, Michibata H, Akatsuka H, et al. Genomic origin and transcriptional regulation of two variants of cGMP-binding cGMP-specific phosphodiesterases. Eur J Biochem 1999; 262: 866-73.
139. D'Andrea MR, Qiu Y, Haynes-Johnson D, Bhattacharjee S, Kraft P, Lundeen S. Expression of PDE11A in normal and malignant human tissues. J Histochem Cytochem 2005; 53: 895-903.
140. Horvath A, Boikos S, Giatzakis C, Robinson-White A, Groussin L, Griffin KJ, et al. A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia. Nat Genet 2006; 38: 794-800.
141. Baxendale R, Burslem F, Phillips S. Phosphodiesterase type 11 (PDE11) cellular localisation: progress towards defining a physiological role in testis and/or reproduction. J Urol 2001; 165 (suppl 5): 340.
142. Degerman E, Belfrage P, Manganiello VC. Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3). J Biol Chem 1997; 272: 6823-6.
143. Salanova M, Chun SY, Iona S, Puri C, Stefanini M, Conti M. Type 4 cyclic adenosine monophosphate-specific phosphodiesterases are expressed in discrete subcellular compartments during rat spermiogenesis. Endocrinology 1999; 140: 2297-306.
144. Yan C, Zhao AZ, Sonnenburg WK, Beavo JA. Stage and cell-specific expression of calmodulin-dependent phosphodiesterases in mouse testis. Biol Reprod 2001; 64: 1746-54.
145. Farooqui SM, Al-Bagdadi F, Houslay MD, Bolger GB, Stout R, Specian RD, et al. Surgically induced cryptorchidism-related degenerative changes in spermatogonia are associated with loss of cyclic adenosine monophosphate- dependent phosphodiesterases type 4 in abdominal testes of rats. Biol Reprod 2001; 64: 1583-9.
146. Lefievre L, de Lamirande E, Gagnon C. Presence of cyclic nucleotide phosphodiesterases PDE1A, existing as a stable complex with calmodulin, and PDE3A in human spermatozoa. Biol Reprod 2002; 67: 423-30.
147. Levallet G, Levallet J, Bouraima-Lelong H, Bonnamy PJ. Expression of the cAMP-phosphodiesterase PDE4D isoforms and age-related changes in follicle-stimulating hormone-stimulated PDE4 activities in immature rat sertoli cells. Biol Reprod 2007; 76: 794-803.
148. Mancina R, Filippi S, Marini M, Morelli A, Vignozzi L, Salonia A, et al. Expression and functional activity of phosphodiesterase type 5 in human and rabbit vas deferens. Mol Hum Reprod 2005; 11: 107-15.
149. Milhoua P, Lowe D, Melman A. In: Mulcahy JJ, Ed. Male Sexual Function, Totowa, NJ: Humana Press Inc. 2007; pp. 1-45.
150. Valente EG, Vernet D, Ferrini MG, Qian A, Rajfer J, Gonzalez-Cadavid NF. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. Nitric Oxide 2003; 9: 229-44.
151. Pellestor F, Paulasova P, Hamamah S. Peptide nucleic acids (PNAs) as diagnostic devices for genetic and cytogenetic analysis. Curr Pharm Des 2008; 14(24): 2439-44.
152. Srivani P, Usharani D, Jemmis ED, Sastry GN. Subtype selectivity in phosphodiesterase 4 (PDE4): a bottleneck in rational drug design. Curr Pharm Des 2008; 14(36): 3854-72.
153. Zhang HT. Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs. Curr Pharm Des 2009; 15(14): 1688-98.